Semaglutide, the active ingredient in Ozempic and Wegovy, is a glucagon-like peptide-1 (GLP-1) receptor agonist taken as a once-weekly injection. It’s administered with a tiny needle that punctures ...

This article was reviewed by Darragh O’Carroll, MD. Key takeaways: Semaglutide nausea is common: About 20 percent of Ozempic® ...

Semaglutide patent in India expires in March 2026, enabling over 50 branded generic versions to enter the market, likely ...

Ozempic (R) was approved by Health Canada in 2018. Ozempic (R) is indicated for the once-weekly treatment of adult patients with type 2 diabetes mellitus to improve glycemic control.

Add Yahoo as a preferred source to see more of our stories on Google. A vial with injectable compound and a syringe. - Anna Hoychuk // Shutterstock Compounded semaglutide is a medication that’s custom ...

Semaglutide has already become more than just a “vanity drug.” Clinical trials like SUSTAIN-6 and FLOW have shown it can slash the risk of kidney disease, reduce major heart attacks, and even lower ...

Indian drugmaker Dr Reddy's Laboratories is likely to launch its generic semaglutide injection in the country in March ​under ...

Semaglutide's patent expiry in India could sharply reduce the cost of popular weight-loss and diabetes injections.

(Competitive Insight/Unsplash) While GLP-1 drugs such as Wegovy and Ozempic are now being broadly championed and widely used, ...

The drug behind Ozempic has been found to restore joint cartilage in osteoarthritis, through a mechanism that works ...

Novo Nordisk announced today that Health Canada has approved Ozempic® (semaglutide injection) to reduce the risk of major adverse cardiovascular (CV) events (CV death, non-fatal myocardial infarction ...